Navigation Links
Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference
Date:3/29/2013

SEATTLE, March 29, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that it has been chosen to present at the 2013 Future Leaders in the Biotech Industry Conference.  Gregory A. Demopulos , M.D., chairman and chief executive officer, is scheduled to present at 9:30 a.m. Eastern Time on Friday, April 5, 2013.

The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at www.omeros.com.  

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Omeros to Present at Deutsche Bank Securities Health Care Conference
2. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
3. Omeros to Present at Jefferies 2012 Global Healthcare Conference
4. Omeros Announces Proposed Public Offering of Common Stock
5. Omeros Prices $30 Million Public Offering of Common Stock
6. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
7. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
8. Omeros Announces Discovery in MASP-2 Program
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... -- Columbia Laboratories, Inc. (Nasdaq: CBRX ) (" ... pharmaceutical company focused on pharmaceuticals for women,s health, today ... ROTH Conference, which will take place from March 8-11 ... Point, California . Management,s presentation will take place ... (12:00 p.m. Eastern Time) in the Promenade room. ...
(Date:3/3/2015)... 3, 2015 /CNW/ - Sante Medical Hair Restoration is ... hair transplantation. The ARTAS Robotic System ... effectively extracts hair for transplantation. This latest development ... results, with no linear scar. "The ... of hair restoration surgery." says Dr. Louis ...
(Date:3/3/2015)... Mar. 03, 2015 Research and Markets ... of the "Telemedicine and Mobile Healthcare Solutions, ... - 2020" report to their offering. ... are all terms that pertain to the use ... provide remote clinical/non-clinical healthcare services. They form the ...
Breaking Medicine Technology:No linear scar. Permanent results. 2Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 2Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 3
... ANTONIO, April 17, 2012  Mission Pharmacal announced today ... technology licensing agreement with EffRx Pharmaceuticals SA, Freienbach, ... (alendronate sodium) Effervescent Tablets in the ... Drug Administration recently approved BINOSTO to treat osteoporosis ...
... SPRING, Md., April 16, 2012     Sunpeaks Ventures, Inc. ... Ventures") and its wholly owned subsidiary Healthcare Distribution Specialists, ... be an official exhibitor at the Thrombosis and Hemostasis ... May 3-5, 2012 at the Hyatt Regency Chicago.  ...
Cached Medicine Technology:Mission Pharmacal and EffRx Bring New Osteoporosis Medication to the United States and Canada 2Mission Pharmacal and EffRx Bring New Osteoporosis Medication to the United States and Canada 3Mission Pharmacal and EffRx Bring New Osteoporosis Medication to the United States and Canada 4Sunpeaks Ventures to Exhibit Clotamin at the first-ever Thrombosis and Hemostasis Summit of North America 2
(Date:3/3/2015)... Dan E. Chambers, an experienced Los Angeles criminal ... recently spoke on the radio to give his insights into ... Independent Journal Review radio show “The Right Mics” chose Chambers ... and now as a criminal defense attorney would provide him ... and sentencing of this high-profile case. , During the ...
(Date:3/3/2015)... The report “Alopecia – Pipeline Review, ... for Alopecia. Alopecia is the loss of hair. Alopecia ... of alopecia. Causes for alopecia include aging, genetics, illness, ... include male pattern hair loss, female diffuse hair loss, ... classified as focal or diffuse and by the presence ...
(Date:3/3/2015)... The first week of March is Sleep ... event brings recognition to a rarely discussed problem that ... to the Centers for Disease Control , 70 million ... another. Too little or unrestful sleep is associated with ... depression, and even a higher likelihood of obesity. ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 The ... better predict antidepressant treatment outcomes for patients with ... than any of the individual genes that comprise ... investigators from the Mayo Clinic and Assurex Health, ... , The proprietary technology of the GeneSight ...
(Date:3/3/2015)... 03, 2015 The North ... to grow from $1,224.6 million to $1,694.6 ... 2014 and 2019. , Browse through the ... market for an analysis of industry trends ... tables and figures., http://www.micromarketmonitor.com/market/north-america-application-delivery-network-adn-7381582251.html , ...
Breaking Medicine News(10 mins):Health News:Dan E. Chambers Gives Radio Interview Providing Insights into American Sniper Guilty Verdict 2Health News:Dan E. Chambers Gives Radio Interview Providing Insights into American Sniper Guilty Verdict 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 4Health News:Medicationdiscountcard.com recognizes sleep awareness week with discounts on sleep meds including Ambien, Lunesta, and Sonata 2Health News:Medicationdiscountcard.com recognizes sleep awareness week with discounts on sleep meds including Ambien, Lunesta, and Sonata 3Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 2Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 3Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 4Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 5Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 6Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 2Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 3
... who will respond best to interferon beta treatments , ... explain why some multiple sclerosis (MS) patients respond to ... Starting with 206 southern European patients with relapsing-remitting MS, ... compared the DNA of patients whose symptoms were reduced ...
... largest comparison of blood samples collected from healthy individuals ... common Toxoplasma gondii parasite, carried by cats and farm ... report on the study, conducted among U.S. military personnel ... and Johns Hopkins Childrens Center appears in the January ...
... wetlands of southeast Chicago are still being exposed to ... research team reports. The chemicals do not appear to ... findings appear in the current issue of the Journal ... biosciences scientist Jeff Levengood led the study. Levengood, a ...
... Websites with a Turn-Key Solution for Health Portal ... ... Jan. 16 HealthCare.com,( http://www.healthcare.com ), the leading healthcare provider directory ... MediResource ( http://www.mediresource.com ), a leading creator and,syndicator of interactive health ...
... (TSX:,DAX) (NASDAQ: DRAX ) has received approval from ... Course Issuer Bid (NCIB) to,purchase up to 4,072,054 common ... in the public float as at January 14, 2008.,As ... were issued and,outstanding., Purchases may begin on January ...
... Will Analyze Campaign Speeches and Ads During,Presidential Symposium ... 16 Just prior to the primary,elections in ... and clinician Drew Westen, Ph.D., will describe the,emotional ... the Presidential,Symposium of the American Psychoanalytic Association,s 2008 ...
Cached Medicine News:Health News:DNA Analysis Could Help Customize Treatments for MS 2Health News:Toxoplasma infection increases risk of schizophrenia, study suggests 2Health News:Herons persist in Chicago wetlands despite exposure to banned chemicals 2Health News:Herons persist in Chicago wetlands despite exposure to banned chemicals 3Health News:HealthCare.com & MediResource Partner to Distribute and License Health Content, Directory and Tools 2Health News:HealthCare.com & MediResource Partner to Distribute and License Health Content, Directory and Tools 3Health News:DRAXIS Share Buyback Approved by TSX 2Health News:DRAXIS Share Buyback Approved by TSX 3Health News:DRAXIS Share Buyback Approved by TSX 4Health News:2008 Presidential Campaign on the Couch 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: